Close menu




July 23rd, 2021 | 11:37 CEST

CureVac, XPhyto Therapeutics, BioNTech, NanoRepro - Continuous testing or vaccination or both?

  • Biotechnology
Photo credits: pixabay.com

Public confusion reigns. The pandemic seems to be locked in chains over the summer, and the population is happy about initial relief with incidences below 10. But now, the first vacationers are already coming back, partly from risk or mutation areas and have to go for testing again as vaccinated persons. It is often forgotten that even those who have been fully vaccinated can be carriers of the virus and can also fall ill, so it should be clear to everyone that personal protective measures must continue to be kept high. Our life with the COVID virus will last much longer than many want to believe...

time to read: 5 minutes | Author: André Will-Laudien
ISIN: CUREVAC N.V. O.N. | NL0015436031 , XPHYTO THERAPEUTICS | CA98421R1055 , BIONTECH SE SPON. ADRS 1 | US09075V1026

Table of contents:


    CureVac NV - A new attempt against the pandemic

    For the Tuebingen-based biotech Company CureVac, the cards are not particularly good. Because no matter how you turn it around: CureVac's current position without a marketable product is poor - yet many are still clinging to the hope that the situation will change for the better, especially concerning the second-generation COVID-19 vaccine currently in development. But it's not just CureVac that continues to develop the vaccine; everyone else is doing it, of course. As always, the first prize goes to the fastest.

    Doubts among investors also put the share under a lot of pressure last week, but at a reduced level, there are also speculators hoping for better news and taking a few shares from the market. Against this background is the current market capitalization of more than USD 10 billion justified? Of course CureVac can quickly justify this valuation if it can present a good idea against COVID virus mutations or other diseases. So far, too little of that is within reach.

    Hope is undoubtedly one of the reasons why CureVac's share price has not long since fallen to new lows. A rise in the share price above the crash gap could even provide positive chart impulses - as unjustified as these may currently look fundamentally. The share, therefore, remains a casino stock for the time being, i.e. in our opinion, the price will swing digitally with every announcement.

    XPhyto Therapeutics - Entry into the biosensor market and expansion of the diagnostics portfolio

    Again, groundbreaking news at XPhyto Therapeutics: For a total of EUR 3.7 million, they are prospectively acquiring 3a-diagnostics GmbH, Frickenhausen, a development partner for diagnostics. XPhyto has already been actively collaborating with 3a on various research topics since April 2020. The focus is on the joint development and commercialization of cost-effective and easy-to-use biosensor screening tests and associated development platforms for rapidly detecting infectious diseases. 3a has developed a pipeline of peptide-based biosensor screening tests for bacterial and viral infectious diseases. These include stomatitis, peri-implantitis, periodontitis, scarlet fever and influenza. Positive detection of the causative pathogen results in the enzymatic release of an extreme (but safe) bitter compound. 3a has also developed a scalable next-generation microbial-enzymatic screening tool for high-throughput identification of biosensor targets to facilitate the rapid development of new tests.

    Hugh Rogers, CEO of XPhyto, said, "We have worked closely with the team at 3a-diagnostics on several diagnostic products and have been able to find them to be a very innovative and focused partner. The successful development and recent launch of the Covid-ID Lab 25-minute PCR test is an excellent example of our fruitful collaboration. We strongly believe that this acquisition will lead to strong synergies. It will further advance XPhyto's diagnostic pipeline and support our long-term commercial growth plans."

    The first product-related result of the collaboration is the 25-minute Covid-19 PCR test introduced in March 2021 with European market approval, which is already being used in Berlin. Overall, the merger is expected to generate significant synergies in research, development, and production and significantly improved margins for marketable products, such as the 25-minute Covid-ID Lab test. In addition, the acquisition is expected to contribute to the accelerated commercialization of products in 3a's near-market development pipeline. 3a's intellectual property, including patents, know-how, expertise and third-party contracts, will be transferred to XPhyto at the time of the acquisition closing. 3a-diagnostics has an attractive pipeline, an experienced team and is highly regarded for its work in developing and commercializing innovative diagnostic products.

    The XPhyto share has recently attracted a few sellers. The price, however, seems to find a sound basis in the area of CAD 1.60 to take off again now. At current levels, the market cap is only about CAD 110 million. With the current pace of research topics, a blockbuster could be beckoning around the corner at any time!

    BioNTech SE - This share is unstoppable

    Number 1 in vaccination centers and also sales leader worldwide. With Pfizer on board, BioNTech is going like clockwork. The Company is currently gaining a partner in South Africa to increase its availability on the African continent. South African Company Biovac will take over the final manufacturing step, filling and packaging the vaccine, and support distribution in the 55 countries of the African Union, BioNTech and its US partner Pfizer announced Wednesday.

    The tech transfer and all other preparatory activities will begin immediately. Biovac is expected to complete more than 100 million doses of the vaccine at full-scale operations annually. Supplies to Cape Town are to come from the Marburg plant, among others. First deliveries are planned for early next year. The BioNTech and Pfizer network now spans 3 continents with more than 20 production sites.

    Meanwhile, BioNTech shares are already celebrating new highs almost daily. Group sales are estimated at around USD 13-15 billion in 2021. With a P/E of just under 5, it is in good Company among pharmaceutical stocks. Hold!

    NanoRepro AG - What will happen to the war chest?

    Many are asking: What is next for the Marburg-based Company? After all, the broad marketing of the rapid tests for home use must be considered a failure. From the record high of EUR 22.40 reached at the beginning of March, the provider's share price of rapid medical tests has meanwhile lost almost 75%. The figures of the recently presented Annual Report 2020 provide little help in interpreting this, as the revenues of EUR 16.93 million are significantly above previous levels. Still, the real boost in sales is not due until 2021. Most recently - driven by the cooperation with Viromed - there was talk of revenues between EUR 250 and 400 million and an operating result in a range of EUR 60 to 100 million. We are therefore very curious about the half-year figures in September.

    For NanoRepro, what has been achieved so far still means a hugely good 2021, but the capital market is looking to the future. The Company is not yet showing its cards concerning new strategic goals. Meanwhile, the stock market value is around EUR 76 million, roughly equal to the Company's current cash. If the right news about the dividend in 2022 comes or another acquisition-related use of cash makes the rounds, the share price can pick up again from a standing start. Keep an eye on it!


    The companies presented here are in the field of human medicinal, pharmaceutical research. While BioNTech and CureVac occupy the field of COVID in blockbuster size, the approach of NanoRepro and XPhyto is much broader but also much smaller. What makes Xphyto so exciting is its good diagnostic thematic diversity and exciting segments.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author



    Related comments:

    Commented by Stefan Feulner on January 14th, 2022 | 11:44 CET

    BioNTech, Defence Therapeutics, PAION - Seizing the momentum

    • Biotechnology

    The Corona pandemic brought biotechnology to the forefront of society's consciousness, especially since the first vaccines were created in German laboratories. However, the biotech spectrum is much broader than pandemic vaccine research. In addition to research in medicine, the sector is playing an increasingly important role in environmental protection, agriculture and the ongoing climate change.

    Read

    Commented by Armin Schulz on January 12th, 2022 | 13:42 CET

    Bayer, XPhyto Therapeutics, MorphoSys - Which pharmaceutical companies bring returns?

    • Biotechnology

    Most recently, the pharmaceutical industry has been accused of being greedy and getting rich off Corona. While it is true that 2021 has been dominated by vaccine news, the industry can do much more than just produce vaccines against Corona. Handelsblatt ran a headline on January 10, "In the shadow of Corona," citing the growing number of cancers over the past several years. This year, more than 45 new drugs are expected to hit the market to help fight cancer and genetic defects, among other things. Today, we look at three companies that do not make Corona vaccines.

    Read

    Commented by André Will-Laudien on January 12th, 2022 | 11:03 CET

    Valneva, Cardiol Therapeutics, Novavax: Hitting the nail on the head!

    • Biotechnology

    What is the correlation between the development of drugs or vaccines and the price of the company in question on the stock market? Difficult to answer because there is an almost infinite number of research areas in the field of biotechnology. Not all of them are at the center of media interest, while some topics, in contrast, experience true hype phases. COVID-19 is a viral disease that is to be overcome with all available research resources, and the attention on the capital markets is correspondingly high. Those who can demonstrate success in this area achieve high prices and valuations. But who will deliver the ultimate vaccine or a revolutionary drug to treat infected people? Lots of speculation, risks and opportunities in equal measure. We take a look at some interesting companies.

    Read